Evidence map›Paper›PMID 37865098›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2023

Macrophages, MIFs, and MSCs: Defining an MOA in murine experimental asthma.

Jacques Galipeau

Open access · greenAbstract readComment
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Apoptotic MSCs, COX2/PGE2 and clinical efficacy in Crohn fistula.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jacques GalipeauUniversity of Wisconsin School of Medicine and Public Health, University of Wisconsin in Madison, Madison, WI, USA. Electronic address: jgalipeau@wisc.edu.
University of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanistically defined attributes of primed MSCs as here described not only provide a novel use case of MIF activated MSCs that can address the potency shortcomings of generic culture-adapted MSCs for acute lung injury but also provide some intriguing "Rosetta Stone" insights on plausible in vivo physiology of MSCs with host innate effectors such as macrophages in response to inflammation.

Indexed as

AsthmaMacrophage Migration-Inhibitory FactorsMesenchymal Stem Cell TransplantationAnimalsCalgranulin AHumansInflammationIntramolecular OxidoreductasesMacrophagesMiceSignal TransductionCalgranulin AIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, human

Identifiers

PMID37865098
PMCPMC10638068
OpenAlexW4387825519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.